Click here to get full coverage on Viatris Reports Second Quarter 2025 Results and Reiterates 2025 Financial Guidance - PR Newswire

Viatris Reports Second Quarter 2025 Results and Reiterates 2025 Financial Guidance  PR Newswire

Viatris Reports Second Quarter 2025 Results and Reiterates 2025 Financial Guidance - PR Newswire

Click here to get full coverage on Viatris, Inc. (VTRS) Achieves Key Clinical Milestones in Ophthalmology, Pain, Women’s Health - Yahoo Finance

Viatris, Inc. (VTRS) Achieves Key Clinical Milestones in Ophthalmology, Pain, Women’s Health  Yahoo Finance

Viatris, Inc. (VTRS) Achieves Key Clinical Milestones in Ophthalmology, Pain, Women’s Health - Yahoo Finance

Click here to get full coverage on Insider Purchase: Chief Executive Officer of $VTRS Buys 22,000 Shares | VTRS Stock News - Quiver Quantitative

Insider Purchase: Chief Executive Officer of $VTRS Buys 22,000 Shares | VTRS Stock News  Quiver Quantitative

Insider Purchase: Chief Executive Officer of $VTRS Buys 22,000 Shares | VTRS Stock News - Quiver Quantitative

Click here to get full coverage on Trend Review: Is VTRS stock risky to hold now - July 2025 Closing Moves & Long-Term Growth Plans - خودرو بانک

Trend Review: Is VTRS stock risky to hold now - July 2025 Closing Moves & Long-Term Growth Plans  خودرو بانک

Trend Review: Is VTRS stock risky to hold now - July 2025 Closing Moves & Long-Term Growth Plans - خودرو بانک

Click here to get full coverage on Viatris (VTRS) Valuation in Focus After Creation of New Chief Administrative and Transformation Officer Role - simplywall.st

Viatris (VTRS) Valuation in Focus After Creation of New Chief Administrative and Transformation Officer Role  simplywall.st

Viatris (VTRS) Valuation in Focus After Creation of New Chief Administrative and Transformation Officer Role - simplywall.st

Click here to get full coverage on Viatris Sets $0.12 Dividend Payout for September 15: Key Dates and Details Revealed - Stock Titan

Viatris Sets $0.12 Dividend Payout for September 15: Key Dates and Details Revealed  Stock Titan

Viatris Sets $0.12 Dividend Payout for September 15: Key Dates and Details Revealed - Stock Titan

Click here to get full coverage on Why Viatris (VTRS) Stock Is Falling Today - Yahoo Finance

Why Viatris (VTRS) Stock Is Falling Today  Yahoo Finance

Why Viatris (VTRS) Stock Is Falling Today - Yahoo Finance

Click here to get full coverage on Viatris Provides Update on Phase 3 Study of MR-139 for Blepharitis - PR Newswire

Viatris Provides Update on Phase 3 Study of MR-139 for Blepharitis  PR Newswire

Viatris Provides Update on Phase 3 Study of MR-139 for Blepharitis - PR Newswire

Click here to get full coverage on Q2 Earnings Roundup: Viatris (NASDAQ:VTRS) And The Rest Of The Generic Pharmaceuticals Segment - Yahoo Finance

Q2 Earnings Roundup: Viatris (NASDAQ:VTRS) And The Rest Of The Generic Pharmaceuticals Segment  Yahoo Finance

Q2 Earnings Roundup: Viatris (NASDAQ:VTRS) And The Rest Of The Generic Pharmaceuticals Segment - Yahoo Finance

Click here to get full coverage on Viatris Announces Appointment of David Simmons to the Company's Board of Directors - PR Newswire

Viatris Announces Appointment of David Simmons to the Company's Board of Directors  PR Newswire

Viatris Announces Appointment of David Simmons to the Company's Board of Directors - PR Newswire

Click here to get full coverage on Goldman Sachs Reiterates a Hold Rating on Viatris (VTRS) With a $10 PT - Yahoo Finance

Goldman Sachs Reiterates a Hold Rating on Viatris (VTRS) With a $10 PT  Yahoo Finance

Goldman Sachs Reiterates a Hold Rating on Viatris (VTRS) With a $10 PT - Yahoo Finance

Click here to get full coverage on Viatris Announces Positive Top-Line Results from Phase 3 LYNX-2 Trial of MR-142 in Keratorefractive Patients With Visual Disturbances Under Mesopic, Low-Contrast Conditions - PR Newswire

Viatris Announces Positive Top-Line Results from Phase 3 LYNX-2 Trial of MR-142 in Keratorefractive Patients With Visual Disturbances Under Mesopic, Low-Contrast Conditions  PR Newswire

Viatris Announces Positive Top-Line Results from Phase 3 LYNX-2 Trial of MR-142 in Keratorefractive Patients With Visual Disturbances Under Mesopic, Low-Contrast Conditions - PR Newswire

Click here to get full coverage on Viatris (VTRS) Tops Q2 Earnings and Revenue Estimates - Yahoo Finance

Viatris (VTRS) Tops Q2 Earnings and Revenue Estimates  Yahoo Finance

Viatris (VTRS) Tops Q2 Earnings and Revenue Estimates - Yahoo Finance

Click here to get full coverage on Viatris Announces Quarterly Dividend - PR Newswire

Viatris Announces Quarterly Dividend  PR Newswire

Viatris Announces Quarterly Dividend - PR Newswire

Click here to get full coverage on Viatris (VTRS) Announces Positive Top-line Results from VEGA-3 - Yahoo Finance

Viatris (VTRS) Announces Positive Top-line Results from VEGA-3  Yahoo Finance

Viatris (VTRS) Announces Positive Top-line Results from VEGA-3 - Yahoo Finance

Click here to get full coverage on Viatris Announces Five Data Presentations on Novel Fast-Acting Meloxicam (MR-107A-02) at PAINWeek 2025 Conference - PR Newswire

Viatris Announces Five Data Presentations on Novel Fast-Acting Meloxicam (MR-107A-02) at PAINWeek 2025 Conference  PR Newswire

Viatris Announces Five Data Presentations on Novel Fast-Acting Meloxicam (MR-107A-02) at PAINWeek 2025 Conference - PR Newswire

Click here to get full coverage on Viatris Inc. (VTRS): One of the Cheap Quarterly Dividend Stocks to Buy Now - Yahoo Finance

Viatris Inc. (VTRS): One of the Cheap Quarterly Dividend Stocks to Buy Now  Yahoo Finance

Viatris Inc. (VTRS): One of the Cheap Quarterly Dividend Stocks to Buy Now - Yahoo Finance

Click here to get full coverage on Viatris Reports First Quarter 2025 Results and Reaffirms 2025 Outlook - PR Newswire

Viatris Reports First Quarter 2025 Results and Reaffirms 2025 Outlook  PR Newswire

Viatris Reports First Quarter 2025 Results and Reaffirms 2025 Outlook - PR Newswire

Click here to get full coverage on Viatris Files Supplemental New Drug Applications to Japan's Ministry of Health, Labor and Welfare for the Approval of EFFEXOR® for the Treatment of Generalized Anxiety Disorder - PR Newswire

Viatris Files Supplemental New Drug Applications to Japan's Ministry of Health, Labor and Welfare for the Approval of EFFEXOR® for the Treatment of Generalized Anxiety Disorder  PR Newswire

Viatris Files Supplemental New Drug Applications to Japan's Ministry of Health, Labor and Welfare for the Approval of EFFEXOR® for the Treatment of Generalized Anxiety Disorder - PR Newswire

Click here to get full coverage on Global Healthcare Giant Viatris Creates New C-Suite Role to Drive Digital Transformation Strategy - Stock Titan

Global Healthcare Giant Viatris Creates New C-Suite Role to Drive Digital Transformation Strategy  Stock Titan

Global Healthcare Giant Viatris Creates New C-Suite Role to Drive Digital Transformation Strategy - Stock Titan

Click here to get full coverage on VTRS STOCK DEADLINE TOMORROW: Suffer Losses on Viatris - GlobeNewswire

VTRS STOCK DEADLINE TOMORROW: Suffer Losses on Viatris  GlobeNewswire

VTRS STOCK DEADLINE TOMORROW: Suffer Losses on Viatris - GlobeNewswire

Click here to get full coverage on Viatris Announces Positive Results from Phase 3 Study of Investigational XULANE LO™ Low Dose Patch for Birth Control in Women of Childbearing Potential - PR Newswire

Viatris Announces Positive Results from Phase 3 Study of Investigational XULANE LO™ Low Dose Patch for Birth Control in Women of Childbearing Potential  PR Newswire

Viatris Announces Positive Results from Phase 3 Study of Investigational XULANE LO™ Low Dose Patch for Birth Control in Women of Childbearing Potential - PR Newswire

Click here to get full coverage on Analysts Estimate Viatris (VTRS) to Report a Decline in Earnings: What to Look Out for - Yahoo Finance

Analysts Estimate Viatris (VTRS) to Report a Decline in Earnings: What to Look Out for  Yahoo Finance

Analysts Estimate Viatris (VTRS) to Report a Decline in Earnings: What to Look Out for - Yahoo Finance

Click here to get full coverage on Did Viatris’ (VTRS) Executive Reshuffle Centralize Transformation or Signal a Deeper Strategic Shift? - simplywall.st

Did Viatris’ (VTRS) Executive Reshuffle Centralize Transformation or Signal a Deeper Strategic Shift?  simplywall.st

Did Viatris’ (VTRS) Executive Reshuffle Centralize Transformation or Signal a Deeper Strategic Shift? - simplywall.st

Click here to get full coverage on Covering The Flaws In The Viatris Undervaluation Argument (NASDAQ:VTRS) - Seeking Alpha

Covering The Flaws In The Viatris Undervaluation Argument (NASDAQ:VTRS)  Seeking Alpha

Covering The Flaws In The Viatris Undervaluation Argument (NASDAQ:VTRS) - Seeking Alpha

Click here to get full coverage on Viatris (NASDAQ:VTRS) Reports Sales Below Analyst Estimates In Q1 Earnings, But Stock Soars 8% - Yahoo Finance

Viatris (NASDAQ:VTRS) Reports Sales Below Analyst Estimates In Q1 Earnings, But Stock Soars 8%  Yahoo Finance

Viatris (NASDAQ:VTRS) Reports Sales Below Analyst Estimates In Q1 Earnings, But Stock Soars 8% - Yahoo Finance

Click here to get full coverage on Viatris Deadline: VTRS Investors with Losses in Excess of $100K Have Opportunity to Lead Viatris Inc. Securities Fraud Lawsuit - PR Newswire

Viatris Deadline: VTRS Investors with Losses in Excess of $100K Have Opportunity to Lead Viatris Inc. Securities Fraud Lawsuit  PR Newswire

Viatris Deadline: VTRS Investors with Losses in Excess of $100K Have Opportunity to Lead Viatris Inc. Securities Fraud Lawsuit - PR Newswire

Click here to get full coverage on Notable ETF Inflow Detected - SPYD, CVS, VTRS, HPQ - Nasdaq

Notable ETF Inflow Detected - SPYD, CVS, VTRS, HPQ  Nasdaq

Notable ETF Inflow Detected - SPYD, CVS, VTRS, HPQ - Nasdaq

Click here to get full coverage on Viatris Inc. (VTRS): Among Billionaire Ken Fisher’s Healthcare Stock Picks with Massive Upside Potential - Yahoo Finance

Viatris Inc. (VTRS): Among Billionaire Ken Fisher’s Healthcare Stock Picks with Massive Upside Potential  Yahoo Finance

Viatris Inc. (VTRS): Among Billionaire Ken Fisher’s Healthcare Stock Picks with Massive Upside Potential - Yahoo Finance

Click here to get full coverage on VTRS Down on Late-Stage Study Failure of Eye Disease Drug - July 21, 2025 - Zacks Investment Research

VTRS Down on Late-Stage Study Failure of Eye Disease Drug - July 21, 2025  Zacks Investment Research

VTRS Down on Late-Stage Study Failure of Eye Disease Drug - July 21, 2025 - Zacks Investment Research

Click here to get full coverage on Generic Pharmaceuticals Stocks Q4 Teardown: Viatris (NASDAQ:VTRS) Vs The Rest - Yahoo Finance

Generic Pharmaceuticals Stocks Q4 Teardown: Viatris (NASDAQ:VTRS) Vs The Rest  Yahoo Finance

Generic Pharmaceuticals Stocks Q4 Teardown: Viatris (NASDAQ:VTRS) Vs The Rest - Yahoo Finance

Click here to get full coverage on Viatris Inc. (VTRS) Stock Forecasts - Yahoo Finance

Viatris Inc. (VTRS) Stock Forecasts  Yahoo Finance

Viatris Inc. (VTRS) Stock Forecasts - Yahoo Finance

Click here to get full coverage on Viatris: The Problem With The Business Model (NASDAQ:VTRS) - Seeking Alpha

Viatris: The Problem With The Business Model (NASDAQ:VTRS)  Seeking Alpha

Viatris: The Problem With The Business Model (NASDAQ:VTRS) - Seeking Alpha

Click here to get full coverage on Day 5 of Gains Streak for Viatris Stock with 19% Return (vs. -14% YTD) [8/13/2025] - Trefis

Day 5 of Gains Streak for Viatris Stock with 19% Return (vs. -14% YTD) [8/13/2025]  Trefis

Day 5 of Gains Streak for Viatris Stock with 19% Return (vs. -14% YTD) [8/13/2025] - Trefis

Click here to get full coverage on Goldman Sachs Initiates Coverage of Viatris (WBAG:VTRS) with Neutral Recommendation - Nasdaq

Goldman Sachs Initiates Coverage of Viatris (WBAG:VTRS) with Neutral Recommendation  Nasdaq

Goldman Sachs Initiates Coverage of Viatris (WBAG:VTRS) with Neutral Recommendation - Nasdaq

Click here to get full coverage on Viatris: A Contrarian Bet With Virtually No Downside (NASDAQ:VTRS) - Seeking Alpha

Viatris: A Contrarian Bet With Virtually No Downside (NASDAQ:VTRS)  Seeking Alpha

Viatris: A Contrarian Bet With Virtually No Downside (NASDAQ:VTRS) - Seeking Alpha

Click here to get full coverage on Viatris stock down on late-stage trial setback (VTRS:NASDAQ) - Seeking Alpha

Viatris stock down on late-stage trial setback (VTRS:NASDAQ)  Seeking Alpha

Viatris stock down on late-stage trial setback (VTRS:NASDAQ) - Seeking Alpha

Click here to get full coverage on David Einhorn's Greenlight Capital adds FLR, VSCO, exits VTRS, among other trades (FLR:NYSE) - Seeking Alpha

David Einhorn's Greenlight Capital adds FLR, VSCO, exits VTRS, among other trades (FLR:NYSE)  Seeking Alpha

David Einhorn's Greenlight Capital adds FLR, VSCO, exits VTRS, among other trades (FLR:NYSE) - Seeking Alpha

Click here to get full coverage on VTRS STOCK NEWS: Stockholders With Large Losses Should Contact Robbins LLP for Information About the Lead Plaintiff Deadline in the Viatris Inc. Class Action - PR Newswire

VTRS STOCK NEWS: Stockholders With Large Losses Should Contact Robbins LLP for Information About the Lead Plaintiff Deadline in the Viatris Inc. Class Action  PR Newswire

VTRS STOCK NEWS: Stockholders With Large Losses Should Contact Robbins LLP for Information About the Lead Plaintiff Deadline in the Viatris Inc. Class Action - PR Newswire

Click here to get full coverage on Viatris Strengthens Board with Ex-Pfizer President and PPD Chief Who Drove $17.4B Acquisition - Stock Titan

Viatris Strengthens Board with Ex-Pfizer President and PPD Chief Who Drove $17.4B Acquisition  Stock Titan

Viatris Strengthens Board with Ex-Pfizer President and PPD Chief Who Drove $17.4B Acquisition - Stock Titan

Click here to get full coverage on Viatris Inc. (VTRS) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit - PR Newswire

Viatris Inc. (VTRS) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit  PR Newswire

Viatris Inc. (VTRS) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit - PR Newswire

Click here to get full coverage on $VTRS Earnings Preview: Recent $VTRS Insider Trading, Hedge Fund Activity, and More - Nasdaq

$VTRS Earnings Preview: Recent $VTRS Insider Trading, Hedge Fund Activity, and More  Nasdaq

$VTRS Earnings Preview: Recent $VTRS Insider Trading, Hedge Fund Activity, and More - Nasdaq

Click here to get full coverage on Viatris Poised to Report Q2 Earnings: What's in Store for the Stock? - TradingView

Viatris Poised to Report Q2 Earnings: What's in Store for the Stock?  TradingView

Viatris Poised to Report Q2 Earnings: What's in Store for the Stock? - TradingView

Click here to get full coverage on VIATRIS INC. (NASDAQ: VTRS) SHAREHOLDER ALERT Bernstein - GlobeNewswire

VIATRIS INC. (NASDAQ: VTRS) SHAREHOLDER ALERT Bernstein  GlobeNewswire

VIATRIS INC. (NASDAQ: VTRS) SHAREHOLDER ALERT Bernstein - GlobeNewswire

Click here to get full coverage on Daily Dividend Report: BR,APO,VTRS,L,PAYC - Nasdaq

Daily Dividend Report: BR,APO,VTRS,L,PAYC  Nasdaq

Daily Dividend Report: BR,APO,VTRS,L,PAYC - Nasdaq

Click here to get full coverage on Viatris (VTRS) Reports Earnings Tomorrow: What To Expect - TradingView

Viatris (VTRS) Reports Earnings Tomorrow: What To Expect  TradingView

Viatris (VTRS) Reports Earnings Tomorrow: What To Expect - TradingView

Click here to get full coverage on Earnings week ahead: AMD, PLTR, PFE, DIS, O, ET, SHOP, GILD, MCD, CAT, VTRS, BP, UBER, CGC, and more - Seeking Alpha

Earnings week ahead: AMD, PLTR, PFE, DIS, O, ET, SHOP, GILD, MCD, CAT, VTRS, BP, UBER, CGC, and more  Seeking Alpha

Earnings week ahead: AMD, PLTR, PFE, DIS, O, ET, SHOP, GILD, MCD, CAT, VTRS, BP, UBER, CGC, and more - Seeking Alpha

Click here to get full coverage on Viatris (VTRS) Reports Earnings Tomorrow: What To Expect - FinancialContent

Viatris (VTRS) Reports Earnings Tomorrow: What To Expect  FinancialContent

Viatris (VTRS) Reports Earnings Tomorrow: What To Expect - FinancialContent

Click here to get full coverage on SA analyst downgrades: VTRS, MRVL, MAR, NTR, CRSP, DB, VRSK, OCSL - Seeking Alpha

SA analyst downgrades: VTRS, MRVL, MAR, NTR, CRSP, DB, VRSK, OCSL  Seeking Alpha

SA analyst downgrades: VTRS, MRVL, MAR, NTR, CRSP, DB, VRSK, OCSL - Seeking Alpha

Click here to get full coverage on Viatris Q1 Earnings Review: Shares Are Up, Time To Sell (Rating Downgrade) (VTRS) - Seeking Alpha

Viatris Q1 Earnings Review: Shares Are Up, Time To Sell (Rating Downgrade) (VTRS)  Seeking Alpha

Viatris Q1 Earnings Review: Shares Are Up, Time To Sell (Rating Downgrade) (VTRS) - Seeking Alpha

Click here to get full coverage on Why Viatris (VTRS) Stock Is Up Today - FinancialContent

Why Viatris (VTRS) Stock Is Up Today  FinancialContent

Why Viatris (VTRS) Stock Is Up Today - FinancialContent

Click here to get full coverage on VTRS Investors: Robbins LLP Reminds Viatris Inc. Stockholders of the Class Action Lawsuit on Behalf of Investors - GlobeNewswire

VTRS Investors: Robbins LLP Reminds Viatris Inc. Stockholders of the Class Action Lawsuit on Behalf of Investors  GlobeNewswire

VTRS Investors: Robbins LLP Reminds Viatris Inc. Stockholders of the Class Action Lawsuit on Behalf of Investors - GlobeNewswire

Click here to get full coverage on Why Viatris (VTRS) Stock Is Falling Today - TradingView

Why Viatris (VTRS) Stock Is Falling Today  TradingView

Why Viatris (VTRS) Stock Is Falling Today - TradingView

Click here to get full coverage on Viatris Announces Q2 2025 Earnings Call: Key Details for Investors Released - Stock Titan

Viatris Announces Q2 2025 Earnings Call: Key Details for Investors Released  Stock Titan

Viatris Announces Q2 2025 Earnings Call: Key Details for Investors Released - Stock Titan

Click here to get full coverage on Viatris Stock Rises as Q2 Earnings & Revenues Beat Estimates - Zacks Investment Research

Viatris Stock Rises as Q2 Earnings & Revenues Beat Estimates  Zacks Investment Research

Viatris Stock Rises as Q2 Earnings & Revenues Beat Estimates - Zacks Investment Research

Click here to get full coverage on Goldman Sachs Initiates Coverage of Viatris (BMV:VTRS) with Neutral Recommendation - Nasdaq

Goldman Sachs Initiates Coverage of Viatris (BMV:VTRS) with Neutral Recommendation  Nasdaq

Goldman Sachs Initiates Coverage of Viatris (BMV:VTRS) with Neutral Recommendation - Nasdaq

Click here to get full coverage on VTRS Q1 Earnings Call: Pipeline Advances, Tariff Risks, and Strategic Cost Review - FinancialContent

VTRS Q1 Earnings Call: Pipeline Advances, Tariff Risks, and Strategic Cost Review  FinancialContent

VTRS Q1 Earnings Call: Pipeline Advances, Tariff Risks, and Strategic Cost Review - FinancialContent

Click here to get full coverage on Viatris Reports Second Quarter 2025 Results and Reiterates 2025 Financial Guidance - Yahoo Finance

Viatris Reports Second Quarter 2025 Results and Reiterates 2025 Financial Guidance  Yahoo Finance

Viatris Reports Second Quarter 2025 Results and Reiterates 2025 Financial Guidance - Yahoo Finance

Click here to get full coverage on VIATRIS INC. (NASDAQ: VTRS) DEADLINE ALERT: Bernstein - GlobeNewswire

VIATRIS INC. (NASDAQ: VTRS) DEADLINE ALERT: Bernstein  GlobeNewswire

VIATRIS INC. (NASDAQ: VTRS) DEADLINE ALERT: Bernstein - GlobeNewswire

Click here to get full coverage on Viatris Deadline Today: Rosen Law Firm Urges Viatris Inc. (NASDAQ: VTRS) Stockholders With Large Losses to Contact the Firm for Information About Their Rights - Business Wire

Viatris Deadline Today: Rosen Law Firm Urges Viatris Inc. (NASDAQ: VTRS) Stockholders With Large Losses to Contact the Firm for Information About Their Rights  Business Wire

Viatris Deadline Today: Rosen Law Firm Urges Viatris Inc. (NASDAQ: VTRS) Stockholders With Large Losses to Contact the Firm for Information About Their Rights - Business Wire

Click here to get full coverage on Levi & Korsinsky Notifies Viatris Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - VTRS - PR Newswire

Levi & Korsinsky Notifies Viatris Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - VTRS  PR Newswire

Levi & Korsinsky Notifies Viatris Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - VTRS - PR Newswire

Click here to get full coverage on 3 Reasons VTRS is Risky and 1 Stock to Buy Instead - The Globe and Mail

3 Reasons VTRS is Risky and 1 Stock to Buy Instead  The Globe and Mail

3 Reasons VTRS is Risky and 1 Stock to Buy Instead - The Globe and Mail

Click here to get full coverage on Viatris Gains China Approval for COPD Drug Yupelri, Triggers $7.5M Payment to Theravance BioPharma - Yahoo Finance

Viatris Gains China Approval for COPD Drug Yupelri, Triggers $7.5M Payment to Theravance BioPharma  Yahoo Finance

Viatris Gains China Approval for COPD Drug Yupelri, Triggers $7.5M Payment to Theravance BioPharma - Yahoo Finance

Click here to get full coverage on Ventas (VTR) Beats Q2 FFO and Revenue Estimates - Yahoo Finance

Ventas (VTR) Beats Q2 FFO and Revenue Estimates  Yahoo Finance

Ventas (VTR) Beats Q2 FFO and Revenue Estimates - Yahoo Finance

Click here to get full coverage on Thursday 5/15 Insider Buying Report: CTEV, VTRS - Nasdaq

Thursday 5/15 Insider Buying Report: CTEV, VTRS  Nasdaq

Thursday 5/15 Insider Buying Report: CTEV, VTRS - Nasdaq

Click here to get full coverage on Greenlight Capital Announces Q2 2025 Trades: New Positions in FLR and VSCO, Exit From VTRS - Benzinga

Greenlight Capital Announces Q2 2025 Trades: New Positions in FLR and VSCO, Exit From VTRS  Benzinga

Greenlight Capital Announces Q2 2025 Trades: New Positions in FLR and VSCO, Exit From VTRS - Benzinga

Click here to get full coverage on JPMorgan Upgrades Ventas (VTR) to “Overweight” with $72 Price Target - Yahoo Finance

JPMorgan Upgrades Ventas (VTR) to “Overweight” with $72 Price Target  Yahoo Finance

Viatris Inc (VTRS)

Price Chart

Key Statistics

Technicals

About VTRS

Latest News

Viatris Reports Second Quarter 2025 Results and Reiterates 2025 Financial Guidance - PR Newswire

Viatris, Inc. (VTRS) Achieves Key Clinical Milestones in Ophthalmology, Pain, Women’s Health - Yahoo Finance

Insider Purchase: Chief Executive Officer of $VTRS Buys 22,000 Shares | VTRS Stock News - Quiver Quantitative

Advanced Charts

Top Gainers

Top Losers